Retatrutide Side Effects: What Clinical Trials Have Actually Reported
Direct answer: Published retatrutide trials have most often reported gastrointestinal adverse events such as nausea, diarrhea, vomiting, and constipation. In Phase 2 studies, these events were generally mild to moderate and occurred more often in some higher-exposure or faster-escalation groups. A recently published Phase 3 trial adds a larger safety record, but no trial result should be transferred to an unverified research material or treated as individual medical guidance.
Retatrutide is an investigational peptide agonist studied at the GIP, GLP-1, and glucagon receptors. “Side effects” is a search phrase; clinical papers usually report adverse events, serious adverse events, discontinuations, laboratory observations, and prespecified safety measures. Those categories are related, but they are not interchangeable.
The retatrutide chemical structure guide explains the molecule and lipidated side chain. The retatrutide half-life guide addresses concentration decline. Neither structural design nor half-life can predict an individual adverse-event outcome.
What the Phase 2 obesity trial reported
The 48-week Phase 2 obesity trial indexed by NIH PubMed (PMID 37366315) reported that the most common adverse events in retatrutide groups were gastrointestinal. The abstract describes them as dose-related and mostly mild to moderate, and it reports that a lower starting-dose strategy partially reduced those events. It also reports dose-dependent increases in heart rate that peaked at week 24 and then declined.
Those statements describe the trial population, formulation, administration protocol, monitoring schedule, and analysis. They do not mean that every participant experienced an event, that all gastrointestinal events had the same severity, or that a catalog material shares the clinical product’s safety profile.
What the type 2 diabetes trial added
A separate Phase 2 trial in adults with type 2 diabetes, indexed by NIH PubMed (PMID 37385280), reported mild-to-moderate gastrointestinal adverse events in 67 of 190 participants assigned to retatrutide groups, compared with 6 of 45 assigned to placebo and 16 of 46 assigned to dulaglutide. The retatrutide percentage varied substantially among its trial groups, which is one reason a single pooled number should not replace the group-level record.
The two Phase 2 trials addressed different populations and comparators. One cannot be used to “correct” the other. A useful evidence table retains population, trial duration, group design, event definition, and comparator beside each result.
| Public study record | Population, size, and duration | Actual safety result reported in the public abstract | What can and cannot be compared |
|---|---|---|---|
| Phase 2 obesity trial — NCT04881760; PMID 37366315 | 338 adults with obesity or overweight plus a weight-related condition; 48 weeks | Gastrointestinal adverse events were the most common, dose-related, mostly mild to moderate, and partially mitigated by a 2 mg rather than 4 mg starting dose. Dose-dependent heart-rate increases peaked at week 24 and later declined. | The abstract does not report one universal gastrointestinal-event percentage. Its population and escalation groups differ from the diabetes trials. |
| Phase 2 type 2 diabetes trial — NCT04867785; PMID 37385280 | 281 randomized adults; 190 received retatrutide, 45 placebo, and 46 dulaglutide; 36 weeks | Mild-to-moderate gastrointestinal events occurred in 67/190 retatrutide participants (35%), ranging from 13% to 50% across retatrutide groups; 6/45 placebo participants (13%); and 16/46 dulaglutide participants (35%). No severe hypoglycemia or deaths were reported. | The pooled 35% retatrutide value hides large differences among dose and escalation groups. The dulaglutide comparison belongs only to this protocol. |
| TRIUMPH-2 Phase 3 — NCT05929079; PMID 42810372 | 1,152 randomized adults with obesity and type 2 diabetes; 80 weeks | Diarrhea: 27%, 34%, and 34% for 4, 9, and 12 mg versus 13% placebo. Nausea: 14%, 21%, and 28% versus 8%. Permanent discontinuation due to adverse events or death: 4%, 12%, and 8% versus 5%. Investigators judged all seven deaths unrelated to study intervention. | These are assigned-group results from a longer Phase 3 protocol. The combined discontinuation category does not establish that every event was caused by retatrutide. |
What the Phase 3 record changes
The TRIUMPH-2 Phase 3 trial was indexed by NIH PubMed (PMID 42810372) in October 2026. The matching ClinicalTrials.gov record (NCT05929079) identifies it as a completed randomized, double-blind, placebo-controlled Phase 3 trial with 1,152 enrolled participants. The publication abstract reports permanent treatment discontinuation due to adverse events or death in 4% of the 4 mg group, 12% of the 9 mg group, 8% of the 12 mg group, and 5% of the placebo group.
That larger trial improves the available human evidence, but it does not erase earlier studies or create a universal risk percentage. “Adverse events or death” is the publication’s combined discontinuation category; it should not be rewritten as a count of treatment-caused events without the paper’s event-level analysis. Trial enrollment criteria and monitoring also limit transfer to populations outside the protocol.
How to read the safety record
First, separate frequency from severity. A commonly reported event may still be mostly mild or moderate, while an uncommon event can be clinically important. Second, distinguish an event reported after assignment from an event judged related to the study drug. Third, retain the exact trial group and denominator. Percentages from small groups can move substantially with only a few participants.
The retatrutide FDA-status article tracks investigational status separately from trial results. The matching Retatrutide catalog record identifies a research material, while the GLP-1 peptide collection is a navigation category. Neither is evidence that a supplied lot reproduces a clinical formulation, exposure, outcome, or safety profile. Lot-specific analytical fields belong in the COA library.
Research limitations
The evidence summarized here comes from controlled human trials of defined investigational formulations. Adverse-event collection, escalation design, trial duration, participant selection, and statistical summaries differ. Published abstracts also compress the full event record. This article does not provide medical advice, administration instructions, an individual risk estimate, or evidence about a NEXTWAVE PEPTIDES batch.
Frequently asked questions
What side effects were most common in retatrutide trials?
Gastrointestinal events, including nausea, diarrhea, vomiting, and constipation, were prominent in published Phase 2 records. Frequency and severity varied by trial and assigned group.
Were the reported events always severe?
No. The Phase 2 publications describe most gastrointestinal events as mild to moderate. Serious events, discontinuations, and common events must be read as separate categories.
Does a trial adverse-event table describe research-grade retatrutide?
No. It describes the investigational product and protocol used in that trial. A catalog name or analytical certificate does not establish clinical equivalence.
Is retatrutide FDA approved?
Approval status is a separate, time-sensitive question. The linked FDA-status article explains how to check the current official record rather than inferring approval from a trial phase.
NEXTWAVE PEPTIDES provides research-material and documentation records for laboratory reference; it does not convert clinical findings into product claims.